Juraj Adamik

Juraj Adamik, PhD, currently serves as a Principal Scientist at Merck since September 2024, following a tenure as Senior Scientist at RAPT Therapeutics from March 2022 to October 2024. Prior experience includes a Research Scientist role at the Parker Institute for Cancer Immunotherapy, where Juraj established expertise in various immunological methods and contributed to research on immune checkpoint blockade and T cell responses. Juraj's career began at the University of Pittsburgh School of Medicine as a Postdoctoral Researcher, focusing on the effects of small molecule epigenetic inhibitors on bone-tumor dynamics. Educational qualifications include a PhD in Cell/Cellular and Molecular Biology from Duquesne University.